Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia
Stopped early · Phase 3
Conditions studied: Ventilator-Associated Pneumonia (VAP)
In brief
This is a Phase 3, multicenter, prospective, randomized, open-label, study to compare the safety and efficacy of intravenous (IV) ceftolozane/tazobactam with that of IV piperacillin/tazobactam in the treatment of ventilator-associated pneumonia (VAP) in adult participants .
Key facts
- Study ID
- NCT01853982
- Run by
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- People needed
- 4
- Starts
- 2013-06-14
- Expected to finish
- 2013-12-08
- Last updated by the study team
- 2018-11-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study site — Jacksonville, Florida, United States
- Study site — Chicago, Illinois, United States
- Study site — Baltimore, Maryland, United States
- Study site — Duluth, Minnesota, United States
- Study site — Omaha, Nebraska, United States
- Study site — Jamaica, New York, United States
- Study site — The Bronx, New York, United States
- Study site — Cleveland, Ohio, United States
- Study site — Oklahoma City, Oklahoma, United States
- Study site — Abington, Pennsylvania, United States
- Study site — Nashville, Tennessee, United States
- Study site — Herston, Queensland, Australia
- Study site — Meadowbrook, Queensland, Australia
- Study site — Nambour, Queensland, Australia
- Study site — Southport, Queensland, Australia
- Study site — Woolloongabba, Queensland, Australia
- Study site — Auckland, New Zealand
- Study site — Christchurch, New Zealand
- Study site — Wellington, New Zealand
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.